Welcome to our dedicated page for Ir-Med SEC filings (Ticker: IRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IR-Med, Inc. filings document the regulatory disclosures of a Nevada medical-technology issuer developing non-invasive AI-driven infrared spectroscopy devices. Recent Form 8-K reports cover material definitive agreements, private placements of common stock and warrants, exemptions from securities registration, and related capital-structure changes tied to financing activity.
The filings also record executive compensation and employment-agreement amendments, board and officer governance matters, insider participation in securities purchases, warrant terms, common-stock issuance details and exhibits to material agreements. These disclosures frame the company's public-company obligations around financing, compensation, governance and securities compliance.
IR-Med, Inc. entered a Securities Purchase Agreement for a private placement of 14,070,644 common shares at $0.0031 per share and warrants to buy up to 7,035,322 additional shares at $0.03 per share, raising gross proceeds of $43,619 when the deal closed.
Several directors, including Oded Bashan and other board members, participated by purchasing most of the shares and warrants on the same terms. The five-year warrants are exercisable immediately. The company also disclosed that Chief Executive Officer Ran Ziskind resigned effective February 3, 2026, citing disagreements with the company’s strategic direction, management approach, and certain employment matters.
IR-Med, Inc. reported that it has amended employment terms for its CEO and CFO and is facing significant financial pressures that have delayed required SEC reporting. Effective December 1, 2025, CEO Ran Ziskind moved from a fixed salary to an hourly rate of NIS 37 per hour, which the board may raise up to NIS 300 per hour if a significant funding round is secured. CFO Sharon Levkoviz also shifted from a reduced fixed salary to an hourly rate of NIS 185 per hour.
The company disclosed that due to current financial difficulties it did not file its Q3 2025 Form 10-Q by the deadline. IR-Med is evaluating alternatives to address its liquidity needs and intends to resume timely SEC filings once its financial challenges are resolved, but it gives no assurance on the timing or outcome of these efforts.
IR-Med, Inc. reported a private financing in which it entered into a Securities Purchase Agreement with investors on September 14, 2025. The company sold 1,562,500 shares of common stock at $0.016 per share and issued Warrants to purchase up to 781,250 additional shares at an exercise price of $0.05 per share, generating aggregate gross proceeds of $25,000. The transaction closed on September 16, 2025.
The company’s Chief Executive Officer, Ran Ziskind, participated by purchasing 937,500 shares and 468,750 Warrants for a total of $15,000. The Warrants are exercisable immediately and have a five-year term. The securities were issued in a private placement exempt from registration under Section 4(a)(2), Rule 506(b) of Regulation D, and Regulation S, and may not be sold in the United States without registration or a valid exemption.
IR-Med, Inc. reported a private financing in which it entered into a Securities Purchase Agreement with investors on September 14, 2025. The company sold 1,562,500 shares of common stock at $0.016 per share and issued Warrants to purchase up to 781,250 additional shares at an exercise price of $0.05 per share, generating aggregate gross proceeds of $25,000. The transaction closed on September 16, 2025.
The company’s Chief Executive Officer, Ran Ziskind, participated by purchasing 937,500 shares and 468,750 Warrants for a total of $15,000. The Warrants are exercisable immediately and have a five-year term. The securities were issued in a private placement exempt from registration under Section 4(a)(2), Rule 506(b) of Regulation D, and Regulation S, and may not be sold in the United States without registration or a valid exemption.